Chronic Obstructive Pulmonary Disease Market Trends, Share, Size, Demand and Future Outlook
Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Nov-2024 | Report ID: PHAR2417 | Pages: 1 - 235 | Formats*: |
| Category : Pharmaceutical | |||
Global Chronic Obstructive Pulmonary Disease (COPD) Market Introduction and Overview
According to SPER Market Research, the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.
The report includes an in-depth analysis of the Global Chronic Obstructive Pulmonary Disease (COPD) Market, including market size and trends, product mix, applications, and supplier analysis. The chronic inflammatory lung illness known as chronic obstructive pulmonary disease (COPD) makes it difficult for air to leave the lungs. Coughing, wheezing, mucus production, and trouble breathing are some of the symptoms of COPD. Chronic obstructive pulmonary disease is a group of lung illnesses that can cause breathing difficulties. Emphysema and chronic bronchitis are the two primary types of chronic obstructive pulmonary diseases. Breathing problems are one of the primary indicators of COPD. The rise in COPD cases in populations around the world is one important factor that is expected to hasten the growth and consumer demand of the chronic obstructive pulmonary disease sector.
- Trelegy Ellipta was introduced by GlaxoSmithKline Pharmaceuticals in April 2022 for patients with Chronic Obstructive Pulmonary Disease (COPD). For patients with COPD, Trelegy Ellipta is the first once-daily single-inhaler triple treatment (SITT) available in India.
- Teva announced in February 2022 that the FDA has approved ArmonAir Digihaler inhalation powder, an inhaled corticosteroid (ICS) that is administered through Teva's DigihalerTM device, which has sensors embedded in and connects to a companion mobile application that gives asthmatics information on how to utilize their inhalers.
Market Opportunities and Challenges
Opportunities- The increasing prevalence of chronic obstructive pulmonary disease (COPD) is underscored by a 2019 study from the National Center for Biotechnology Information, which reported 212.3 million cases worldwide. This condition accounted for 3.3 million deaths and resulted in 74.4 million disability-adjusted life years (DALYs). Additionally, the American Lung Association highlighted that in 2018, 9.0 million adults (3.6% of those aged 18 and older) were affected by chronic bronchitis. Furthermore, 16.4 million adults (6.6%) reported being diagnosed with some form of COPD, including chronic bronchitis and emphysema. As the incidence of COPD continues to rise, significant market growth in treatments and interventions is anticipated in the near future.
Furthermore, the majority of COPD treatments concentrate on controlling symptoms and delaying the illness's progression. Nonetheless, there is a great need for novel and creative treatments that enhance patients' quality of life and yield better results. New COPD treatments, such as gene therapies, biologics, and other cutting-edge methods, have been the focus of research and development in recent years. These medicines possibly address the fundamental causes of COPD and give patients with more effective and focused therapy alternatives.
Challenges-
Expensive treatment: As a chronic illness, COPD frequently necessitates costly, long-term care and specialized treatment. Furthermore, a large number of COPD patients also have other comorbidities, which raises the expense of healthcare even more. Many patients find that the expense of treating COPD is a significant barrier to access, especially in poor nations where insurance coverage is limited and healthcare expenditures are high. This has a detrimental effect on patient outcomes and quality of life since it results in underdiagnosis and undertreatment of the illness.
Market Competitive Landscape
The Global Chronic Obstructive Pulmonary Disease (COPD) Market is highly consolidated. Some of the market key players are Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type, By Treatment Type, By End User |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others. |
COVID-19 Impact on Global Chronic Obstructive Pulmonary Disease (COPD) Market
The global market for chronic obstructive pulmonary disease (COPD) has been greatly impacted by the COVID-19 epidemic, presenting both potential and challenges. Because of their underlying respiratory disorders, people with COPD were at higher risk during the pandemic, which led to more hospitalizations and a greater emphasis on respiratory health. Prioritizing COVID-19 reactions caused healthcare systems to frequently disrupt routine COPD care and management, which impacted patients' access to medications and made their diseases worse.
Key Target Audience:
- Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Healthcare Providers
- Pharmaceutical Companies
- Medical Device Manufacturers
- Researchers and Academia
- Health Insurance Providers
- Government and Regulatory Agencies
Our in-depth analysis of the Global Chronic Obstructive Pulmonary Disease (COPD) Market includes the following segments:
| By Type: | |
| By Treatment Type: | |
| By End User: |
Key Topics Covered in the Report:
- Global Chronic Obstructive Pulmonary Disease (COPD) Market Size (FY’2024-FY’2033)
- Overview of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By Type (Chronic Bronchitis, Emphysema)
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By Treatment Type (Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others)
- Segmentation of Global Chronic Obstructive Pulmonary Disease (COPD) Market By End User (Hospitals, Homecare Settings, Clinics, Others)
- Statistical Snap of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Expansion Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Problems and Obstacles in Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Competitive Landscape in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Impact of COVID-19 and Demonetization on Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Details on Current Investment in Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Competitive Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Prominent Players in the Global Chronic Obstructive Pulmonary Disease (COPD) Market
- SWOT Analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Market
- Global Chronic Obstructive Pulmonary Disease (COPD) Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global Chronic Obstructive Pulmonary Disease (COPD) Market.
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chronic Obstructive Pulmonary Disease (COPD) Market
7. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Type (USD Million) 2020-2033
7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2020-20267.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2027-20337.3. Chronic Bronchitis7.4. Emphysema
8. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Treatment Type (USD Million) 2020-2033
8.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2020-20268.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2027-20338.3. Drugs8.4. Bronchodilator Monotherapy8.5. Short-Acting Beta2-Agonists (SABAS)8.6. Long-Acting Beta2-Agonists (LABAS)8.7. Anti-Cholinergic Agents8.8. Anti-Inflammatory Drugs8.9. Oral And Inhaled Corticosteroids8.10. Anti-Leukotrienes8.11. Surgery8.12. Lung Volume Reduction Surgery (LVRS)8.13. Lung Transplant, Bullectomy8.14. Others
9. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By End User (USD Million) 2020-2033
9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2020-20269.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2027-20339.3. Hospitals9.4. Homecare Settings9.5. Clinics9.6. Others
10. Global Chronic Obstructive Pulmonary Disease (COPD) Market Forecast, 2020-2033 (USD Million)
10.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share
11. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2020-2033 (USD Million)
11.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2020-2026)11.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2027-2033)11.3. Asia-Pacific11.3.1. Australia11.3.2. China11.3.3. India11.3.4. Japan11.3.5. South Korea11.3.6. Rest of Asia-Pacific11.4. Europe11.4.1. France11.4.2. Germany11.4.3. Italy11.4.4. Spain11.4.5. United Kingdom11.4.6. Rest of Europe11.5. Middle East and Africa11.5.1. Kingdom of Saudi Arabia11.5.2. United Arab Emirates11.5.3. Qatar11.5.4. South Africa11.5.5. Egypt11.5.6. Morocco11.5.7. Nigeria11.5.8. Rest of Middle-East and Africa11.6. North America11.6.1. Canada11.6.2. Mexico11.6.3. United States11.7. Latin America11.7.1. Argentina11.7.2. Brazil11.7.3. Rest of Latin America
12. Company Profile
12.1. Pfizer Inc12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments12.2. Merck & Co., Inc12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments12.3. Novartis AG12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments12.4. AstraZeneca12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments12.5. GlaxoSmithKline plc12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments12.6. Roche (F. Hoffmann-La Roche Ltd, Switzerland)12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments12.7. Abbott12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments12.8. Boehringer Ingelheim International GmbH12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments12.9. Biogen12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments12.10. Teva Pharmaceutical Industries Ltd12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Chronic Obstructive Pulmonary Disease (COPD) Market grew in Market size from 2024. The Market is expected to reach USD 33.31 billion by 2033, at a CAGR of 4.68% during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) Market CAGR of 4.68% during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) Market is projected to reach USD 33.31 billion by 2033, growing at a CAGR of 4.68% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Chronic Obstructive Pulmonary Disease (COPD) Market size is USD 33.31 billion from 2024 to 2033.
Chronic Obstructive Pulmonary Disease (COPD) Market is covered By Type, By Treatment Type and By End User
The North America is anticipated to have the highest Market share in the Chronic Obstructive Pulmonary Disease (COPD) Market.
The Key players in the Market include Companies Covered Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
